1 Improving Post-Transplant Communication of New Donor Information Ad Hoc Disease Transmission Advisory Committee Spring 2016.

Slides:



Advertisements
Similar presentations
Operations and Safety Committee Ms. Theresa Daly
Advertisements

Susan N. Hocevar, MD Medical Officer Office of Blood, Organ, and Other Tissue Safety Division of Healthcare Quality and Promotion Investigation Framework.
Is Nucleic Acid Testing for Organ Donors the ‘Right’ Choice? Reference: Humara A, Morrisb M, Blumbergc R, et al. Nucleic acid testing (NAT) of organ donors:
Align OPTN Policies with the 2013 PHS Guideline for Reducing Transmission of HIV, HBV, and HCV Through Solid Organ Transplantation (Resolution 13) Ad Hoc.
Ad Hoc Disease Transmission Advisory Committee Spring 2015.
Proposal to Modify ABO Determination, Reporting, and Verification Requirements Operations and Safety Committee Spring 2015.
Recognizing Seasonal and Geographically Endemic Infections in Organ Donors: Considerations during Living Donor Evaluation (Resolution 16) Ad Hoc Disease.
Top 5 OPTN Policy Violations
PHS GUIDELINE FOR REDUCING TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS, HEPATITIS B VIRUS AND HEPATITIS C VIRUS THROUGH SOLID ORGAN TRANSPLANTATION ACOT.
November 12, 2014 St. Louis, Missouri OPTN Strategic Planning Feedback Board of Directors.
QAPI What Medicare Really Wants? Presented to: Region 7 Presented on: February 13, 2015 Presented by: Gwen McNatt.
Guidance for Recognizing Central Nervous System Infections in Potential Deceased Organ Donors: What to Consider During Donor Evaluation and Organ Offers.
Proposal to Require the Collection of Serum Lipase for all Pancreas Donors (Resolution 5) Pancreas Transplantation Committee Jonathan Fridell, MD, Chair.
Greater Consistency in Candidate and Deceased Donor HLA Typing Requirements Across Organ Types Histocompatibility Committee Spring 2014.
Proposal To Modify Existing or Establish New Requirements for the Psychosocial and Medical Evaluation of all Living Donors Living Donor Committee Spring.
Addressing the Requirements Outlined in the HIV Organ Policy Equity Act Organ Procurement Organization Committee Spring 2015.
1 Operations and Safety Committee Update Fall 2015.
OPTN Strategic Plan Maureen McBride United Network for Organ Sharing August 28, 2012.
Operations and Safety Committee Fall Recent Public Comment Proposals Proposal to Modify ABO Determination, Reporting, and Verification  Did not.
Operations and Safety Committee Update Theresa Daly MS, FNP.
Proposal to Align OPTN Policies with the 2013 PHS Guideline for Reducing Transmission of HIV, HBV, and HCV Through Solid Organ Transplantation Ad Hoc Disease.
Addressing the Requirements Outlined in the HIV Organ Policy Equity Act Organ Procurement Organization Committee Fall 2014.
FDA EID Workshop: Day 2 Organs, Tissues and Cells Melissa A. Greenwald, MD Blood Products Advisory Committee 26 July 2010 Gaithersburg, MD.
Expanding HLA Typing Requirements (Resolution 10) Histocompatibility Committee Dolly Tyan, PhD Chair.
Ad Hoc Disease Transmission Advisory Committee Fall 2014.
1 Revising Kidney Paired Donation Pilot Program Priority Points Kidney Transplantation Committee Fall 2015.
Proposal to Reduce the Reporting Requirements for the Deceased Donor Registration (DDR) Form Organ Procurement Organization Committee Fall 2014.
OPTN Proposal to Require Extra Vessels Disposition Reporting to the OPTN in Five Days of Transplant or Disposal Sponsored by the Operations and Safety.
Proposal to Align OPTN Policies with the 2013 PHS Guideline for Reducing Transmission of HIV, HBV, and HCV Through Solid Organ Transplantation Ad Hoc Disease.
David A. Gerber, MD Professor and Chief Division of Abdominal Transplantation Department of Surgery University of North Carolina at Chapel Hill.
Ad Hoc Disease Transmission Advisory Committee Fall 2014.
Operations and Safety Committee Update Report to Board of Directors June , 2012 Phil Camp, Jr., MD - Chair.
1 Proposal to Increase Committee Terms to Three Years Policy Oversight Committee (POC) Fall 2015.
Operations and Safety Committee Spring  Sharing Patient Safety Data/Lessons Learned  Analysis of patient safety situation data reports  Working.
1 Standardize an Organ Coding System for Tracking of Organs: Requirements for OPO TransNet SM Use Operations and Safety Committee Spring 2016.
1 Kidney Transplantation Committee Spring Recent Public Comment Proposals  OPTN Kidney Paired Donation (KPD) Priority Points  Changes apply.
Operations and Safety Committee Spring  Sharing patient safety data/lessons learned  Analyzing patient safety situation data reports  Working.
1 Infectious Disease Verification to Enhance Patient Safety Operations and Safety Committee.
Guidance for VCA Deceased Donor Authorization (Resolution 7)
Minority Affairs Committee
Guidance on Optimizing VCA Recovery from Deceased Donors
Clarify Informed Consent of Transmittable Conditions
Thoracic Organ Transplantation Committee
Guidance for ABO Subtyping Organ Donors for Blood Groups A and AB
Ad Hoc Disease Transmission Advisory Committee (DTAC) Update
Clarify Informed Consent of Transmittable Conditions
Operations and Safety Committee Update
Addressing HLA Typing Errors
Proposal to Modify Sterile Internal Vessels Label
Proposal to Require the Reporting of Aborted Living Donor Organ Recovery Procedures (Resolution 19) Living Donor Committee Mary Amanda Dew, PhD.
Modify HOPE Act Variance to Include Other Organs
Ad Hoc Disease Advisory Committee Update
Operations and Safety Committee
Living Donor Committee Spring 2014
Guidance on Effective Practices in Broader Distribution
Proposal to Delay the HCC Exception Score Assignment
Operations and Safety Committee
OPO Committee Fall 2014.
OPO Committee Fall 2014.
Living Donor Committee Spring 2014
OPTN/UNOS Living Donor Committee
Clarify Informed Consent of Transmittable Conditions
Vascularized Composite Allograft Transplantation Committee Fall 2014
Living Donor Committee
Living Donor Committee
Operations and Safety Committee Spring 2014
Operations and Safety Committee Spring 2014
Using Whole Genome Sequencing Analysis in California
OPO Committee Fall 2014.
Vascularized Composite Allograft (VCA) Transplantation Committee
Presentation transcript:

1 Improving Post-Transplant Communication of New Donor Information Ad Hoc Disease Transmission Advisory Committee Spring 2016

2 What problem will the proposal solve?  Communication delays or failures about new donor information learned post-transplant have led to transplant recipient morbidity and mortality  Policy requirement: must report PDDTE to patient safety contact and OPTN Improving Patient Safety Portal (IPS)  General policy language allows reporting to vary  Over and under reporting exist  Process doesn’t always function as intended

 Provide more specific reporting guidelines  What types of results  Who needs to receive report  When do they need to receive it  More standardized and efficient communication  Devote resources and attention to most critical results What is the goal of the proposal? 3

Type of ResultsWho Reports Where ReportedTime Frame All results (including negatives) OPOUpload to DonorNet Pathogens of Special Interest Malignancy or other findings highly suggestive of malignancy recognized after procurement OPORecipient(s) Transplant Program Patient Safety Contact (PSC) OPTN Improving Patient Safety Portal (IPS) ASAP but no later than 24 hours after receipt How does the proposal address the problem statement? 4

OPOs must report the following positive results: 5 Report ONLY to the receiving transplant program patient safety contact ASAP but no later than 24 hours after receipt  Serologic, NAT, or antigen results indicating presence of parasites, virus, or fungi  Cultures from the following specimens:  Ascites  Blood  Cerebrospinal fluid (CSF)  Deep wound  Pericardial  Pleural fluid  Tissue  Mycobacterial smears and cultures  Fungal smears and cultures with the exception of Candida species 1  Respiratory samples only to transplant programs receiving lungs* 1 Candida from sterile sites needs to be reported within 24 hours

OPOs must report the following positive results: 6 Report ONLY to the receiving transplant program patient safety contact ASAP but no later than 24 hours after receipt  Urine cultures only to transplant programs receiving kidneys*  Any histopathology results (including negative results) reported post-procurement  All final culture information for any culture results that were reported according to these requirements  Other psycho-social history, medical history, autopsy, testing, and laboratory findings identifying infectious conditions that may adversely affect a potential transplant recipient *Mycobacterial and fungal (with the exception of Candida species) positive results must be reported to the transplant program’s recipient of any organ

Type of ResultsWho Reports Where Reported Time Frame All toxoplasmosis results for donor testing conducted by transplant program (includes negatives) Tx Program Host OPOs Risk of potential transmission of disease or malignancy discovered in living donor Living donor recovery hospital Receiving transplant program PSC OPTN IPS ASAP but no more than seven days after receipt of the new information How does the proposal address the problem statement? 7

 Failure Modes and Effects Analysis (FMEA) conducted on Post Transplant Results Communication  8 process steps: 28 potential failure modes  17 recommendations on 16 highest failure modes  Proposal addresses six of the recommendations Supporting Evidence 8

Supporting Evidence: Communication Gaps Impact Infectious Disease Transmissions What Contributed?  Transplant center delayed contacting the OPO with a suspected donor derived infection  Failure of labs to relay donor results to the OPO and/or transplant center  OPO delay in contacting DTAC or transplant centers  Clerical errors  Test results communicated by OPO to transplant centers was incomplete What happened?  18 of 56 (32%) infectious events (IE) had communication gap or delay  12 of 18 (67%) IE had adverse event  20 out of 29 recipients experienced adverse event  6 deaths R Miller et al, “Communication Gaps Associated with Donor-Derived Infections,” American Journal of Transplantation 15 (2015):

Supporting Evidence: Percent of Deceased Donors Recovered with Case Reported and Proven/Probable Case through 8/21/2015 by Region of Recovery 10

 OPOs and transplant hospitals need to familiarize staff responsible for PDDTE reporting with the new policy  OPOs need to develop a reporting protocol that includes:  Obtaining all results for any deceased donor testing conducted  Uploading all deceased donor testing results to DonorNet  Sharing relevant deceased donor test results with tissue banks  Reporting specified positive test results to the transplant hospital patient safety contact (as soon as possible but no later than 24 hours of receipt)  Reporting specified positive test results to the OPTN (as soon as possible but no later than 24 hours of receipt) How will members implement this proposal? 11

 Transplant hospitals need to:  Report to the host OPO all toxoplasmosis results (including negative results) conducted on deceased donor samples  Continue to report suspected cases of donor-derived transmissions  Living donor recovery hospitals need to:  Report all risk of potential transmission of disease or malignancy as soon as possible but no more than seven days after receipt of the new information  Continue to report suspected cases of donor-derived transmissions How will members implement this proposal? 12

 Promote living donor and transplant recipient safety: This proposal will :  1. Clarify expectations regarding how OPOs report new donor information learned post-transplant  2. Triage direction on how this information is shared to reduce:  Burdens of both sharing and receiving  Perceived desensitization within the community due to the "noise" currently flooding the current reporting system and allow more focus on critical results How does this proposal support the OPTN Strategic Plan? 13

 Many results will not require urgent communication  Routine urine cultures (non-kidney recipient center)  Routine sputum cultures (non-lung recipient center)  Focus on recipient disease rather than donor cultures in reporting to the OPTN  Exception for pathogens where CDC investigation may be able to assist transplant centers  Sharing toxoplasmosis results with all recipient centers  Difficulties with communicating and performing donor testing when done at heart center  Recent recognition that these results are relevant to non-heart recipients Summary 14

 What are both the OPO and transplant hospital experiences in this region with toxoplasmosis testing?  DTAC is considering requiring all OPOs to conduct toxoplasmosis testing to:  Overcome logistical challenges for transplant hospitals to complete the testing  Assure that disease in non-cardiac recipients is not missed  Seeking VCA specific feedback Feedback needed 15

Daniel Kaul MD Committee Chair Susan Tlusty Committee Liaison Questions? 16

Extra Slides 17

 FMEA conducted on Post Transplant Results Communication Supporting Evidence 18 Process Step/ Failure Mode Priority Recommended Action(s) Score Rank 1d. OPO does not get all of the valid information ●OPOs must develop a protocol for tracking and collecting all pending results ●OPOs must post information to DonorNet for transplant center review ●Conduct review of best practices and disseminate 1e. OPO does not follow up on all labs (e.g. pending cultures) 46410●See 1d above 2a. Incomplete information is reported 44811●Develop decision support tool to triage information reporting ●Ensure staff making decisions to send information have adequate expertise and training. ●Post negatives to DonorNet and then call positives using “on call” features within DonorNet. Features allow for or text rather than phone.

 FMEA conducted on Post Transplant Results Communication Supporting Evidence 19 Process Step/ Failure Mode Priority Recommended Action(s) Score Rank 2b. OPO fails to appropriately identify information to report to patient safety contact 29619●See 2a above 4a. Delay in information reaching patient safety contact 5763●Require OPOs to have a protocol 4b. Failure to confirm information transfer 43215●See 4a above 7b. Failure to report potential donor-derived disease transmission event (PDDTE) from transplant hospital 5044●Ongoing educational effort to optimize reporting and minimize burden to members (reducing potential over reporting) (Note: Will be done as part of policy implementation)

Supporting Evidence: Historical Trends of PDDTE Reporting to the OPTN Reports made to OPTN Reports chosen for DTAC review Reports not reviewed % Reviewed71.2%60.7%72.6%84.3%83.4% Donors transmitting proven/probableN/A Intervention without documented transmission (IWDT)N/A Unlikely/ExcludedN/A PossibleN/A Donors transmitting proven/probableN/A12.6%11.3%16.7%17.1% IWDTN/A22.7%25.7%11.6%18.8% Unlikely/ExcludedN/A59.7%53.5%64.6%54.1% PossibleN/A5.0%9.5%7.1%9.9%